The well-documented role of HSP65/60 cross-reactivity in the induction of autoimmune responses that drive atherosclerosis has spurred efforts to develop vaccines aimed at restoring immune tolerance to HSP65/60. This evidence concerns the gene HSPD1 and atherosclerosis.